Takeshi Matsuzaki

Takeshi Matsuzaki

Auto-generated profile, based on publicly available information

Takeshi Matsuzaki

Yakult Central Institute for Microbiological Research, 1790 Yaho, Kunitachi, Tokyo, 1860-8650, Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2007
Verified
Journal Article
Closed access
ATAkimitsu Takagi
Akimitsu Takagi
MWMasatoshi Watanabe
Masatoshi Watanabe
YIYasuhisa Ishii
Yasuhisa Ishii
JMJoji Morita
Joji Morita
YHYoshifumi Hirokawa
Yoshifumi Hirokawa
TSTaizo Shiraishi
Taizo Shiraishi

10 October 2012 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HKHiroaki Konishi
Hiroaki Konishi
ATAkimitsu Takagi
Akimitsu Takagi
AKAkinobu Kurita
Akinobu Kurita
NKNorimasa Kaneda
Norimasa Kaneda
TMTakeshi Matsuzaki
Takeshi Matsuzaki
Background: Advanced ovarian cancer is characterized by peritoneal metastasis and the accumulation of ascites. Peritoneal metastasis of ovarian cancer is a major cause of the negative treatment outcome, as these metastases are resistant to most chemotherapy regimens. The aim of this study was to clarify aggressive pathology of peritoneal metastasis and examine the therapeutic efficacy of a liposomal agent in the model. Methods: A human cancer cell line ES-2 of ovarian clear cell carcinoma, known as a chemotherapy-resistant cancer, was cultured in nonadherent plate to form spheroid and single cell suspension was transplanted into mouse peritoneal cavity. The epidermal growth factor receptor (EGFR) pathways in the cellular aggregates were analyzed both spheroid and ascites. The pharmacokinetics and therapeutic efficacy of CPT-11 (45 mg/kg) and IHL-305 (45 mg/kg), an irinotecan-encapsulated liposome, were examined by intravenous administration. Results: Established peritoneal metastasis model showed an accumulation of ascites. The activation of EGFR and Akt was demonstrated in cellular aggregates both in the spheroid and ascites. In ascites samples, the area under the curve of SN-38, the activated form of CPT-11, was 3.8 times higher from IHL-305-treated mice than from CPT-11-treated mice. IHL-305 prolonged the survival time and decreased the accumulation of ascites and tumor metastasis. The median survival time were 22, 37 and 54 days in the control, CPT-11-treated, and IHL-305-treated mice, respectively. Conclusions: EGFR/Akt pathway contributes to the aggressive progression in ES-2 peritoneal metastasis model and effective delivery into ascites of IHL-305 was thought to useful treatment for ovarian cancer with peritoneal metastasis.

1 February 2011 in Chemistry and Physics of Lipids
Verified
Journal Article
Closed access
TITakashi Iida
Takashi Iida
SOShoujiro Ogawa
Shoujiro Ogawa
HTHideyuki Tamegai
Hideyuki Tamegai
YAYuuki Adachi
Yuuki Adachi
HSHiroaki Saito
Hiroaki Saito
TMTakeshi Matsuzaki
Takeshi Matsuzaki